Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 26, 2019

View Archived Issues

New mouse model for intrahepatic cholangiocellular carcinoma reveals protective effect of Pecam-1

Signaling promotes glucose uptake, brain tumor development

Novel Dyrk1 inhibitor DYR-219 delays the onset of AD-like pathology in 3xTg-AD mice

Artesunate modifies T cells to protect against type 1 diabetes

SNP-162 inhibits growth of sorafenib-resistant liver cancer cell lines

CStone completes registration filing in Australia for phase I trial of CS-3002 in solid tumors

NO-releasing polymer NVN-1000 inhibits HPV DNA replication and progeny virus production

MEIS2 knockdown prevents colorectal cancer cell migration and invasion

Monoclonal antibody P52E03 protects against H7N9 virus challenge

Transgenic expression of human STING mutant in hematopoietic cells provides murine SAVI model

Enrollment ongoing in phase II study of osilodrostat in pediatric patients with Cushing's disease

FIAsp receives European approval for the management of diabetes in adolescents and children

Tanabe initiates first-in-human study of TR1801-ADC

Off-target resistance to TRK inhibitors

Sunshine Lake Pharma describes new farnesoid X receptor agonists

Otago Innovation, University of Copenhagen patent CaMK2A ligands

Anhui New Star Pharmaceutical Development discovers P2Y12 antagonists

New IDO-1 inhibitors identified at Hinova Pharmaceuticals

Boehringer Ingelheim presents ghrelin O-acyltransferase inhibitors

Daewoong's pulmonary fibrosis drug DWN-12088 enters global phase I trial

Phase III BREEZE-AD7 study of baricitinib in atopic dermatitis meets primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...